scispace - formally typeset
K

Keith A. Cengel

Researcher at University of Pennsylvania

Publications -  210
Citations -  12705

Keith A. Cengel is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 34, co-authored 178 publications receiving 10610 citations. Previous affiliations of Keith A. Cengel include University of Illinois at Urbana–Champaign & Hospital of the University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

PTH1-34 blocks radiation-induced osteoblast apoptosis by enhancing DNA repair through canonical Wnt pathway

TL;DR: The results identify a novel role of PTH and canonical Wnt signaling in regulating DSB repair machinery and apoptosis in osteoblasts and shed light on using PTH1–34 or Wnt agonist as possible therapy for radiation-induced osteoporosis.
Journal ArticleDOI

Radioprotective Role in Lung of the Flaxseed Lignan Complex Enriched in the Phenolic Secoisolariciresinol Diglucoside (SDG)

TL;DR: The dietary lignan complex of FS, mainly consisting of the phenolic secoisolariciresinol, is protective against radiation pneumonopathy in vivo while not hindering the tumoricidal effects of radiotherapy.
Journal ArticleDOI

Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.

TL;DR: It is demonstrated that PDT stimulates the nuclear accumulation of both EGFR and STAT3 and that targeting these survival pathways is a potentially promising strategy that could be adapted for clinical trials of PDT for patients with serosal spread of malignancy.
Journal ArticleDOI

JAK1-dependent Phosphorylation of Insulin Receptor Substrate-1 (IRS-1) Is Inhibited by IRS-1 Serine Phosphorylation *

TL;DR: It is suggested that IRS-1 serine phosphorylation may play a counter-regulatory role in pathways outside the insulin signaling system and suggest that the receptor substrate renders it a poorer substrate for JAK1 (Janus kinase-1).
Journal ArticleDOI

Erlotinib pretreatment improves photodynamic therapy of non-small cell lung carcinoma xenografts via multiple mechanisms

TL;DR: It is found that addition of erlotinib to photodynamic therapy (PDT) can improve treatment response in typically erlot inib-resistant NSCLC tumor xenografts, and this data demonstrate that short-duration administration of erLotinib before PDT can greatly improve the responsiveness of even erlotInib- resistant tumors to treatment.